Introduction {#Sec1}
============

Overweight and obesity are pandemic conditions \[[@CR1]\] associated to increased risk for type 2 diabetes, cardiovascular disease, cancer and all cause-mortality \[[@CR2], [@CR3]\], and a dramatic increase in public health expense to their management \[[@CR4], [@CR5]\]. Mediterranean diet seems to be a model to preserve a good health, especially when followed for the life-span. However, the large amount of carbohydrate included in the modern Mediterranean diet could be not adequately metabolized in strongly sedentary people and favor body weight increase \[[@CR6]\]. Several randomized clinical trials carried out in specialized medical setting have clearly shown that a short-term ketogenic diet could be useful to obtain a quick and relatively safe weight loss in selected patients \[[@CR7], [@CR8]\]. Moreover, the efficacy on body weight loss seems to be associated to a large number of positive metabolic changes, potentially useful to mitigate the features of the metabolic syndrome and contrasting the development of type 2 diabetes \[[@CR9], [@CR10]\]. In particular, a recent meta-analysis of randomized clinical trials, showed that ketogenic diets induce a long-term more significant improvement in body weight, diastolic blood pressure, triglycerides and HDL-cholesterol, when compared to low fat diets \[[@CR11]\]. However, there are no many studies testing if this approach could be useful, feasible and safe also in a setting of general medicine \[[@CR12]\]. This scientific question is of primary relevance, given the large prevalence of obesity in general population, that could not be managed in a hospital setting.

In this context, the aim of our study was to evaluate the efficacy and tolerability of a ketogenic diet suggested and monitored in the setting of general practice, in term of long and mid-term weight loss and modification of the main cardiovascular (CV) disease risk factors.

Methods {#Sec2}
=======

General practitioners, well acquainted with VLCK diets methods selected by a senior physician already expert in the tested method, after a further specific training, have carried out this observational study.

The selected patients met the following inclusion requirements: they are aged between 30--69 years, have a BMI between 27--37 kg/m^2^ and an abdominal circumference of 98 cm or more for men and 87 cm or more for women.

The exclusion from this study occurred in case of renal impairment (i.e. creatinine greater or equal to than 1.5 mg/dL), major depressive with eating disorders, serious hepatic impairment, insulin-dependent type 1 diabetes, oral anticoagulant treatment. Furthermore, patients with an ongoing anti-cancer treatment as well as pregnant or breast-feeding women were not taken into account.

The 21.1 % of the subjects was affected by arterial hypertension, the 10 % by impaired fasting glucose; the 6.4 % by type 2 diabetes, the 3.2 % was in secondary prevention for cardiovascular diseases. The 12.2 % had pharmacologically compensated hypothyroidism.

After to have signed a specific informed consent form, eligible patients, at time zero, were subjected to a general medical examination and an evaluation of anthropometric and bio-humoral parameters.

Thirty-seven general practitioners identified, in three months' time, 377 eligible patients (M 21.2 %, W 78.8 %). Among them, 311 were selected, as they were the only participants to the first monitoring visit at 30 days. Sixty-six patients dropped-out for different reasons, but none of which of a clinical matter.

The next monitoring visits were planned first after 3 months and then after 12 months.

The enrolled patients have been subjected to VLCK diet (as implemented by Lignaform), a nutritional regimen is a VLCK diet, based on the use of high biological level protein formulation of milk/egg/legumes origin (peas and NO OGM soybeans), with a content of 15--18 g in proteins, 2--6 g in carbohydrates, 3 g in fats for a caloric intake of 100 kcal. Additionally, vegetables were allowed. The preparations were personally bought by patients.

Our method is articulated in different stages: in the first step we provide a protein intake of 1.2--1.5 g/kg of ideal body weight \[[@CR13]\], in association with low-glycemic index vegetables. Thus, it is a normal-protein regime compared to the ideal weight, but hyper-protein diet in relation to the others nutrients consumed.

Afterwards, the formulations are replaced by natural protein foods and the diet is gradually completed with other aliments on the base of glycemic index following a multiphasic scheme.

Firstly, patients were exclusively treated with formulations and vegetables (stage 1). Then, only one formulation was replaced by a protein aliment (meat, fish, eggs) and vegetables (stage 2). Immediately after, another formulation was substituted with another protein food (conclusion of stage 2). Eventually, patients inserted, in sequential, fruit, dairy products, cereals and legumes (stages 3--4--5--6). The duration of each stage is proportional to weight loss during the ketogenic periods. The last stage (stage 7) consisted in a re-education to the Mediterranean diet based on patient's expenditure of energy.

However, from the very beginning an integration of calcium, magnesium, potassium, omega 3 fatty acids (500 mg) and olive oil is necessary.

The following variables have been measured with standardized methods or calculated at the baseline, at the monitoring visit at 30 days, then after 3 and 12 months: height, weight, body mass index (BMI), waist circumference (WC), index of central obesity (ICO = ratio of waist circumference and height), impedentiometrically estimated fat mass, systolic (SBP), diastolic (DBP) and pulse pressure (PP), thyroid stimulating hormone (TSH), fasting plasma glucose (FPG), glycated haemoglobin (HbA1c), total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), triglycerides, liver transaminases, gamma-glutamyl transferase (gGT), creatinine, estimated glomerular filtration rate (eGFR, CKD-EPI formula), microalbuminuria, uric acid (SUA), serum potassium, sodium, magnesium and calcium.

A complete descriptive analysis was carried out for continuous and categorical parameters. Categorical parameters were compared by the chi-square test followed by the Fisher exact test. Normally distributed parameters were compared with ANOVA for paired and unpaired samples, followed by the Student t-test, while not-normally distributed parameters with Kruskal--Wallys analysis of variance followed by Mann--Whitney U test. The predictor of a more significant weight loss were identified by the application of a logistic regression test. A significance level of 0.05 has been chosen for all tests. All the analyses were carried out with the help of SPSS 21.0, version for Windows.

Results {#Sec3}
=======

The main characteristics of the enrolled patients are resumed in Table [1](#Tab1){ref-type="table"}. Throughout the study, 82.5 % of the patients involved in the study, completed the first 4 week period, 71.1 % the first 12-week period, 52 % continued the protocol until 12 months.Table 1Main anthropometric, haemodynamic and laboratory characteristics of the enrolled subjects at the baseline (value compared between genders)VariableMenWomenAge (years)48.3 ± 10.9\*45.6 ± 9.9Body weight (kg)97.5 ± 10.8\*81.9 ± 10.4Body mass index (kg/m^2^)32.1 ± 2.8\*31.2 ± 3.1Waist circumference (cm)108.3 ± 9.6\*99.6 ± 10.0Index of central obesity0.62 ± 0.050.61 ± 0.06Fat mass (%)41.4 ± 16.3\*37.3 ± 15.9Systolic blood pressure (mmHg)132.5 ± 14.2\*128.0 ± 15.1Dyastolic blood pressure (mmHg)78.9 ± 7.7\*75.9 ± 11.3Pulse pressure (mmHg)53.5 ± 12.852.1 ± 14.6TSH (uUI/mL)2.1 ± 1.32.6 ± 2.5Fasting plasma glucose (mg/dL)104.6 ± 21.8\*95.7 ± 27.0Glycated haemoglobin (%)5.5 ± 0.95.5 ± 0.8Total cholesterol (mg/dL)215.6 ± 35.4211.8 ± 39.3HDL cholesterol (mg/dL)45.2 ± 10.5\*56.3 ± 14.9LDL cholesterol (mg/dL)138.7 ± 31.7132.9 ± 36.1Triglycerides (mg/dl)158.9 ± 75.3\*117.0 ± 67.9AST (U/L)25.0 ± 10.9\*21.2 ± 7.5ALT (U/L)33.3 ± 19.5\*23.4 ± 10.8Gamma glutamyl transferase (U/L)32.6 ± 16.9\*23.2 ± 17.4Creatinine (mg/dL)0.93 ± 0.15\*0.80 ± 0.15Serum uric acid (mg/dL)5.6 ± 1.2\*4.5 ± 1.2Microalbuminuria (mg/L)10.3 ± 7.2\*8.9 ± 9.3Serum potassium (mEq/L)4.9 ± 1.84.3 ± 1.3Serum sodium (mEq/L)139.4 ± 3.8139.2 ± 3.1Serum magnesium (mg/dL)2.0 ± 0.61.9 ± 0.5Serum calcium (mg/dL)8.9 ± 1.28.9 ± 1.2\* p \< 0,05, men vs. women

All the measured anthropometric variables exhibited a similar trend.

Body weight significantly improved from baseline to 4 weeks (−7 ± 5 kg, p \< 0.001), from 4 to 12 weeks (−5 ± 3 kg, p \< 0.001), while no changes were observed from 12 weeks to 12 months (−1 ± 2 kg, p = 0.06). Therefore, after 1 year the subjects experienced a mean total body weight loss of 14 ± 10 kg.

The BMI significantly improved from baseline to 4 weeks (−3 ± 2 kg/m^2^, p \< 0.001), from 4 to 12 weeks (−2 ± 2 kg/m^2^, p \< 0.001), while no changes were observed from 12 weeks to 12 months (−0.2 ± 0.9 kg/m^2^, p = 0.08). Therefore, after 1 year the subjects experienced a mean total body weight loss of 5 ±3 kg/m^2^.

The WC significantly improved from baseline to 4 weeks (−7 ± 4 cm, p \< 0.001), from 4 to 12 weeks (−5 ± 7 cm, p \< 0.001), while no significant changes were observed from 12 weeks to 12 months (−0.2 ± 1.1 cm, p = 0.68), so after 1 year the subjects experienced a mean total body weight loss of 13 ± 7 cm.

The ICO improved from baseline to 4 weeks (−0.04 ± 0.02, p \< 0.001), from 4 to 12 weeks (−0.03 ± 0.04, p \< 0.001), while no significant changes were observed from 12 weeks to 12 months (−0.01 ± 0.04, p = 0.64). Therefore after 1 year the subjects experienced a mean total body weight loss of 0.8 ± 0.4.

The estimated percentage of body fat significantly improved from baseline to 4 weeks (−3.8 ± 3.8 %, p \< 0.001), from 4 to 12 weeks (−3.4 ± 3.5 %, p \< 0.001), while no significant changes were observed from 12 weeks to 12 months (−0.2 ± 1.1 cm, p = 0.89), therefore after 1 year the subjects experienced a mean total body weight loss of 8.1 ± 5.9 % (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Body weight, BMI, waist circumference, and estimated body fat mass changes during the different study phases

Regarding the haemodynamic parameters, SBP significantly improved from baseline to 3 months (−10.5 ± 6.4 mmHg, p \< 0.001) but no changes were observed after 1 year of observation. A similar trend, has been noticed for DBP (−2.2 ± 3.1 mmHg, p \< 0.001) and PP (−8.3 ± 6.2 mmHg, p \< 0.001).

FPG significantly improved from baseline to 4 weeks (−8.7 ± 15.3 mg/dL, p \< 0.001) and no change were observed after 1 year of monitor. Similarly, HbA1c improved from baseline to 3 months (−0.3 ± 0.7 mg/dL, p \< 0.001) and held steady after 1 year of observation.

About lipid parameters, LDL-C significantly improved from baseline to 3 months (−19.5 ± 16.9 mg/dL, p \< 0.001) and we noticed no change after 1 year of observation. A similar trend has been observed for TG (−23.4 ± 30.2 mg/dL, p \< 0.001), while HDL-C improved from baseline to 4 weeks (+1.8 ± 5.6 mg/dL, p = 0.038), and even more after 12 months (+3.5 ± 3.3 mg/dL, p \< 0.001).

As regards the liver parameters, AST significantly improved from 1 to 3 months (−2.2 ± 3.2 U/L, p \< 0.001), and no other changes were marked after 1 year of observation. A similar trend has been observed for ALT (−3.1 ± 5.3 U/L, p \< 0.001), while gamma-GT improved from baseline to 4 weeks (−4.1 ± 5.2 mg/dL, p \< 0.001), with no other significant changes after 1 year of observation.

With reference to renal parameters, estimated glomerular filtration rate (eGFR), creatinine level and microalbuminuria were not significantly modified during the observation period, while uricemia mildly but significantly improved from the 3rd month to the end of the study (−0.4 ± 1.5 mg/dL, p = 0.048).

No significant change has been observed as regards serum level of potassium, sodium and magnesium. However calcemia mildly but significantly decreased from baseline to 30 days (−0.35 ± 0.82 mg/dL, p = 0.001), while it improved in the following period from 30 to 90 days (+0.21 ± 0.71 mg/dL, p = 0.017).

No changes have been observed in the standard urinalysis.

The short-term body weight loss was quicker in men than in women (p \< 0.05), greater in those subjects experiencing a ketonuria in the first period of diet (p \< 0.001), and was directly related to the baseline body weight (RR 1.10, 95 % CI 1.04--1.16, p \< 0.001), and inversely to patient age (RR −0.20, 95 % CI −0.27 to −0.15, p \< 0.001), while the long term body weight loss was greater in those subjects experiencing a ketonuria in the first period of diet (p \< 0.05), and was directly related to the baseline body weight (RR 1.26, 95 % CI 1.27--1.18, p \< 0.001) and body fat mass (RR 1.17, 95 % CI 1.01--1.33, p = 0.033).

Discussion {#Sec4}
==========

The international guidelines for cardiovascular disease prevention suggest, as a first step, the optimization of dietary habits in order to improve the cardiovascular disease risk \[[@CR14], [@CR15]\]. In our study, carried out in the setting of general practice, we observed that a short-term ketogenic diet is able to improve both on the short and long-term a large number of anthropometric, haemodynamic and metabolic parameters related to the cardiovascular disease risk. In particular we examined a significant improvement in body weight, BMI, WC, ICO, estimated body fat, SBP, DBP, PP, FPG, HbA1c, LDL-C, TG and HDL-C levels, that tend to remain stable after 1 year from the end of the short ketogenic period. The mild improvement of uricemia observed in the trial could also have some relevant prognostic implication \[[@CR16]\].

These changes have not been associated to any clinically relevant adverse event.

Our results, in terms of body weight and lipid control improvement, are in good agreement with previous short-term randomized clinical trials comparing the effect of high protein diets to standard protein nutritional regimes \[[@CR17]\]. A more recent meta-analysis of 17 randomized clinical trials involving 1141 obese patients confirmed our observation, showing that low-carb/high protein diets are also associated to a significant improvement of systolic and diastolic BP, basal glycaemia and HbA1c \[[@CR18]\]. Beyond the low intake of carbohydrate, low-fat diets induce improvement in basal insulinemia depending on protein content in the diet itself, as high protein diets are associated to improved insulinemia, and consequently improved glucose metabolism \[[@CR19]\]. The long-term positive effects on body weight and other metabolic parameters observed in our study could be explained by the maintenance of a low-glycaemic index diet after the ketogenic hyperproteic period of the tested method \[[@CR20]\]. Nevertheless, our study has a few relevant limitations worth to be considered.

First, it is not a randomized but an observational clinical trial. Thus, one can say that observed effects are related to the reduction of energy intake per se rather than the tested dietary method \[[@CR21]\].

Moreover, one can argue that the baseline characteristics of the enrolled patients were not homogenous as well as different physician ability to discuss the methods could have influenced the efficacy of the method itself. This can be understood looking at the goal we wanted to reach, that was to mimic real patients that a general practitioner usually cope with.

However, at the best of our knowledge, this is the first report one can find in the literature of the efficacy and tolerability of a short-term ketogenic intervention on overweight and obese patients outside highly specialized centres, with a relatively long follow-up after intervention end \[[@CR22]\].

Conclusion {#Sec5}
==========

With the limitation of an observational study, in our experience a short-term ketogenic diet managed in the setting of general practice seemed to be able to improve a large number of anthropometric, haemodynamic and metabolic parameters related to the cardiovascular disease risk, with improvements maintained also on the long-term \[[@CR23], [@CR24]\]. Further randomized clinical trials are expect to confirm these positive results.
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